The Danish drugmaker Novo Nordisk argues that semaglutide, the active ingredient in Ozempic and Wegovy, are too complex for those manufacturers to make safely.
Related Posts
As Microsoft turns 50, Nadella sees future success built on ability to ‘win the new’
Microsoft is in a strong position 50 years into its existence, but regulations and competitive pressures in artificial intelligence challenge future growth.
CVS, UnitedHealth, Cigna sue to block FTC case over insulin prices
The complaint is the latest move in a bitter legal fight between the U.S.’s three largest so-called pharmacy benefit managers, or PBMs, and the FTC.
Supreme Court allows DOGE to access Social Security data
The dispute concerns efforts by the Department of Government Efficiency, largely led by Elon Musk, to access sensitive data, including Social Security numbers.